Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 6,875

Document Document Title
WO/2021/244638A1
Provided in the present invention are a Fenlean 7 position metabolite, and the preparation and the use thereof. The Fenlean 7 position metabolite of the present invention has a good antioxidant activity and anti-neuroinflammation and neu...  
WO/2021/245253A1
A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more...  
WO/2021/244635A1
Provided in the present invention are a metabolite at position 21 of Fenlean, and the preparation and the use thereof. The metabolite at position 21 of Fenlean of the present invention has a good antioxidant activity and anti-neuroinflam...  
WO/2021/234449A1
New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D, L-proline cocryst...  
WO/2021/227441A1
A compound inhibiting a sodium-glucose cotransporter 1, and a pharmaceutically acceptable salt and a stereoisomer thereof. The compound is used in a pharmaceutical composition. Also disclosed are methods for preparing and using the pharm...  
WO/2021/227439A1
Provided in the present invention are a compound for inhibiting sodium glucose cotransporter 1, and a pharmaceutically acceptable salt and a stereoisomer of the compound. The compound is used for a pharmaceutical composition, and further...  
WO/2021/226276A2
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...  
WO/2021/213500A1
A compound of Formula (I) : (I) or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently ...  
WO/2021/211765A1
A process for the production of dihydronepetalactone including hydrogenating nepetalactone in the presence of a catalytic metal is provided. The catalytic metal may include nickel. The process may be performed in an aqueous medium.  
WO/2021/204175A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...  
WO/2021/200179A1
The present invention provides an actinic-ray-sensitive or radiation-sensitive resin composition comprising (A) a resin which increases in polarity by the action of an acid and (B) a compound which generates an acid upon irradiation with...  
WO/2021/200178A1
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin in which polarity is increased due to acid activity, and (B) a compound which is represented by a specific general f...  
WO/2021/201577A1
The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are...  
WO/2021/193786A1
The present invention provides: a 6-(fluoroalkyl)-3,4-dihydro-2H-pyran-5-carboxylic acid ester derivative represented by a specific formula (3); a method for producing the same; a method for producing a 2-(fluoroalkyl) nicotinic acid der...  
WO/2021/187547A1
The present invention provides a useful compound and a mode suitable as a pharmaceutical agent ingredient thereof, as an agent for treating and/or preventing diseases caused by activation of a DP receptor, particularly as a therapeutic a...  
WO/2021/184123A1
A method of treating a coronavirus infection involves administering an inhibitor of the Neu1 sialidase – G protein-coupled receptor - Matrix metalloproteinase 9 (Neu1-GPCR-MMP9) signaling platform, in particular administering intraveno...  
WO/2021/179088A1
The present disclosure relates to a composition comprising: i) terpenes in a diamond construction for delivering a specific aroma profile; and ii) optionally, at least one cannabinoid. The present disclosure also relates to methods of us...  
WO/2021/175971A1
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucosa.  
WO/2021/170464A1
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R9 represent groups such as hydrogen, halogen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent ...  
WO/2021/170913A1
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...  
WO/2021/163666A1
Disclosed herein are compositions and methods relating to treating, preventing, reducing, and/or inhibiting cancers, infectious diseases, and/or neurological disorders.  
WO/2021/157642A1
The present invention improves the light emission efficiency, driving voltage, and lifespan of an organic electroluminescent element using a delayed fluorescent material. A host material for a delayed fluorescent material and comprising ...  
WO/2021/159015A1
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...  
WO/2021/155748A1
Provided are molecules capable of binding to binding pockets of Plasmodium falciparum hexose transporter (PfHT) or analogs thereof and complexes comprising the same. Also provided herein are inhibitors of PfHT, pharmaceutical composition...  
WO/2021/157593A1
Superior durability is demonstrated by an organic light emitting element that uses a light emitting composition including both a first compound with a PBHT value greater than 0.730 and a second compound for which ES1 is smaller than for ...  
WO/2021/156870A1
Compositions comprising 3-hexen-l-ol are described herein, as well as odor-imparting formulations comprising same and articles-of-manufacturing comprising such compositions or odor-imparting formulations. The compositions comprise trans-...  
WO/2021/149051A1
The present invention provides compounds and herbicidal compositions comprising thereof. Further, use of herbicidal compositions or kit for controlling plant growth is also provided.  
WO/2021/148940A1
The present invention relates to new classes of odorous tetrahydropyran-4-ol derivatives of formula X and/or alkene derivatives thereof of formula Y1 and Y2 which are useful as fragrance or flavor materials in particular in providing cam...  
WO/2021/122558A1
The present invention relates to substituted 4-methylene-tetrahydropyrans, 4-methyl- dihydropyrans and 4-methyl-tetrahydropyrans of formula (I), where the variables are as defined in the claims and description, to a stereoisomer thereof,...  
WO/2021/121925A1
A process for the production of a compound according to Formula (I), such as oleocanthal or oleacein, starting from oleuropein. The process provides the dialdehyde core of oleocanthal, oleacein and their analogues having the required ste...  
WO/2021/110121A1
A treatment method for treating the condition of a subject who benefits from modulating the immune function, the method comprising administering to the subject a pharmaceutically effective amount of an HDAC6 selective inhibitor. The pres...  
WO/2021/111912A1
The purpose of the present invention is to provide a radiation-sensitive resin composition that exhibits a good sensitivity to exposure light and an excellent LWR performance and CDU performance, a method for forming resist patterns, a p...  
WO/2021/106468A1
The purpose of the present invention is to provide a fluorine-containing anionic surfactant having excellent surface tension reduction ability and water solubility due to the use of a fluorine-containing compound composed of a perfluoroa...  
WO/2021/105779A1
The present invention relates to solid compounds also referred to as new solid forms (NSF) of Dapagliflozin (DPG) co-crystals and co-amorphs, wherein the co-former is selected from: a) a carboxylic acid derivative having an amino group i...  
WO/2021/101482A1
The present invention relates to a solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent and at least one pharmaceutically acceptable excipients. Further the present invention provides a method...  
WO/2021/094594A1
A soil treatment formulation having an ethoxylated/propoxylated fatty acid mono-esters of sorbitan, ethylene oxide-propylene oxide copolymer, and compatibilising surfactant selected from an alkoxylated fatty alcohol, alkoxylated fatty al...  
WO/2021/092287A1
Compounds of Formula IA, IB, II, III, IV, and/or V are described herein along with their methods of use. A compound of the present invention may cross-link under physiological conditions and/or in vivo.  
WO/2021/085372A1
An embodiment of the present invention pertains to a resin composition, a compound (Z), an optical filter, or a solid-state imaging device and optical sensor device using the optical filter. The resin composition contains a resin, and a ...  
WO/2021/083209A1
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...  
WO/2021/080015A1
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and metho...  
WO/2021/064189A2
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...  
WO/2021/055849A1
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...  
WO/2021/043951A1
Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein D is covalently attached via a hydroxy group at OR1,...  
WO/2021/045159A1
One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides: a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic ...  
WO/2021/045681A1
The present invention relates to a nanoparticle which is characterized by a photoluminescent amorphous core formed from threonine and polyethylenimine (PEI), and wherein the surface of the core is functionalised with at least one carbohy...  
WO/2021/045682A1
The present invention relates to a colorimetric method for detecting bacterial cells in a sample. The colorimetric method comprises: (a) contacting the sample with nanoparticles to form a mixture, wherein the nanoparticles are characteri...  
WO/2021/037759A1
A novel compound is disclosed. Skin lightening composition comprising said compound and method of skin lightening is disclosed too. In addition, method of synthesizing said novel compound is disclosed.  
WO/2021/026179A1
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...  
WO/2021/024054A1
Techniques regarding enhancing antimicrobial activity of antirheumatic agents by combination therapy are provided. For example, one or more embodiments described herein can regard a chemical composition comprising a polycarbonate polymer...  
WO/2021/018044A1
Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically inv...  

Matches 51 - 100 out of 6,875